6-KThe Wire
Innate Pharma SA files 6-K
Filed May 19, 2026 · 1mo ago · Accession 0001628280-26-036122
Plain English
Innate Pharma S.A. announced its first quarter 2026 financial results, reporting revenue of €22.8 million and a net loss of €19.3 million. The company also provided an update on its clinical development programs and strategic partnerships.
Filing details
- Company
- Innate Pharma SA
- Ticker
- IPHA
- CIK
- 1598599
- Form type
- 6-K
- Filing date
- May 19, 2026
- Report date
- May 19, 2026
- Document
- a260519_6k.htm
- Size
- 21 KB